News | Atrial Fibrillation | May 15, 2018

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk

HRS late-breaking study authors say further investigation is needed to understand the temporal relationship of marijuana and arrhythmias

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018

May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricular fibrillation (VF) and ventricular tachycardia (VT) following an acute myocardial infarction (AMI). The study also reported that marijuana users had a decreased risk of atrial fibrillation (AFib) and in-hospital mortality. The results of the study were presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

Recent federal data reported a stunning 455 percent increase in marijuana consumption among U.S. adults ages 55-64 years and 333 percent in ages over 64 years between 2002 and 2014 [1]. In fact, one in eight Americans say they smoke marijuana [2]. While results of previous studies show links between cannabis use and increases in heart rate and blood pressure, little is known about the cardiac-related effects for heart arrhythmias including VF and VT.  

The study compared clinical profiles and in-hospital outcomes between reported marijuana users vs. non-users from 1994 to 2013. The primary endpoint was VT/VF or cardiac arrest and the secondary endpoint was atrial fibrillation or mortality. The patient group included people between the ages of 18-70 years with a primary diagnosis of AMI (ICD-9-CM code 410.xx) from eight states including California, New York, New Jersey, Vermont, New Hampshire, Colorado, Texas and West Virginia. Patients who used cocaine, methamphetamine or alcohol were excluded from the study. Variables included in a step-forward multivariate logistic regression model included age, race and cardiac risk factors. 

In total, 3,854 of 1,273,897 patients admitted with AMI reported marijuana use. Findings from the study show marijuana users tended to be younger, male and less likely to have coronary artery disease (CAD) or coronary risk factors than non-users. Primary endpoints show that 9.7 percent (n=374) marijuana users and 9.7 percent (n=122,797) non-users experienced VT/VF or cardiac arrest. Secondary endpoints show that 4.5 percent (n=173) marijuana users vs. 8.7 percent (n=110,153) non-users had AFib, and 4 percent (n=135) vs. 6 percent (n=75,311) died, respectively. Despite there being no difference in the risk for VT/VF, researchers found in-hospital mortality was lower in marijuana users and a trend toward decreased risk of AFib was lower in marijuana users. 

"The legalization of marijuana is spreading quickly across the U.S. resulting in more people using it, but we still don’t know the true, long-term impact it has on one’s heart health. Our study is the first to examine the relationship between marijuana use after a heart attack and various arrhythmias and we did not see a negative connection," said senior author Christine Tompkins, M.D., assistant professor of cardiology medicine at University of Colorado School of Medicine. "We are just one step closer to a better understanding of the various heart effects of marijuana, so that we are able to take the necessary actions to provide optimal patient care." 

The authors have noted that future studies are warranted to further understand the temporal relationship of marijuana and arrhythmias in patients with chronic ischemic heart disease, and are actively involved in a prospective observational study. They have also expressed interest in understanding the effects of marijuana in other chronic cardiac conditions, such as congestive heart failure and hypertension. The authors emphasize a need to understand how marijuana affects the heart so as to provide patients with informed choices, particularly since use in adults over the age of 50 years is increasing exponentially.  

Heart Rhythm 2018 is the most comprehensive educational program for heart rhythm professionals, featuring more than 200 educational sessions and more than 140 exhibitors showcasing innovative products and services. For more information: www.hrssessions.org

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

References: 

1. Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and Health, United States, 2002–2014. MMWR Surveill Summ 2016;65 (No. SS-11):1–25. DOI: http://dx.doi.org/10.15585/mmwr.ss6511a1.

2. Gallup, Inc. "In U.S., 45% Say They Have Tried Marijuana." Gallup.com,  19 July 2017, news.gallup.com/poll/214250/say-tried-marijuana.aspx.  

 

#HRS2018 #HRS18

Related Content

The Adagio Medical iCLAS cryoablation system is commercial in Europe and is also part of an ongoing FDA IDE trial in the U.S. #HRS21
News | Atrial Fibrillation | August 09, 2021
August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for...
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...